A Phase 2 Clinical Study of CU-20401

Summary

This is a randomized, double-blind, placebo-controlled Phase Ⅱ clinical study to evaluate the efficacy, safety, and immunogenicity of CU-20401 for Injection in a population with moderate to severe contour elevation or over-fullness due to SMF accumulation.

Timeline

Start

2023-12-20

Primary completion

2024-09-02

Completion

2024-09-02

Outcome

Met primary endpoint

release “In terms of efficacy, primary efficacy endpoint results demonstrated that the treatment efficacy of both the low dosage and high dosage groups of CU-20401 were superior to that of the placebo-controlled group” cutiatx.com ↗

Drugs

Indications

No indication recorded.